Biotech has a new company model: A small team, a big check and a few Chinese assets

The so-called NewCo model of value creation has been around for years, but its use with assets connected to China appears to be increasing, as the world’s second-most populous country experiences a renaissance in its drug development industry.

Raccontata daendpoints.news